Retrospective Analysis of Antiretroviral HIV Treatment Success Based on Medical History or Guided by the Reverse Hybridisation LiPA HIV Genotyping System

Journal of Medical Virology

Volumn 73, Issue 2, 2004, Pages 151-157

  Alvarez, M ^a   García, Federico ^a   Martinez N M ^a   Quero, J Hernández ^b   Louwagie, J ^c   De Brauwer, A ^c   Maroto, M C ^a  

^a HOSPITAL UNIVERSITARIO SAN CECILIO   (Spain)

^b HOSPITAL UNIVERSITARIO VIRGEN DE LAS NIEVES   (Spain)

^c INNOGENETICS   (Belgium)

Author keywords

HIV; LiPA; Mutation; Resistance

Indexed keywords

ABACAVIR; ANTIRETROVIRUS AGENT; CD4 ANTIGEN; DIDANOSINE; INDINAVIR; LAMIVUDINE; NELFINAVIR; NEVIRAPINE; PROTEINASE INHIBITOR; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; SAQUINAVIR; STAVUDINE; ZALCITABINE; ZIDOVUDINE;

ADULT; ARTICLE; CONTROLLED STUDY; EVALUATION; FEMALE; GENOTYPE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYBRIDIZATION; LIPA HIV GENOTYPING SYSTEM; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; RETROSPECTIVE STUDY; STATISTICAL ANALYSIS; STATISTICAL SIGNIFICANCE; TREATMENT FAILURE; VIRUS LOAD; VIRUS RESISTANCE; VIRUS TYPING;

ADULT; ANTI-HIV AGENTS; CD4 LYMPHOCYTE COUNT; DRUG RESISTANCE, VIRAL; FEMALE; GENETICS, POPULATION; GENOTYPE; HIV; HIV INFECTIONS; HIV PROTEASE; HIV-1 REVERSE TRANSCRIPTASE; HUMANS; MALE; MICROBIAL SENSITIVITY TESTS; NUCLEIC ACID HYBRIDIZATION; POINT MUTATION; RETROSPECTIVE STUDIES; TREATMENT OUTCOME; VIRAL LOAD; VIRAL PROTEINS;

EID: 2142819962     PISSN: 01466615     EISSN: None     Source Type: Journal    
DOI: 10.1002/jmv.20069     Document Type: Article

References (24)

1. Baxter JD, Mayers DL, Wentworth DN, Neaton JD, Hoover ML, Winters MA, Mannheimer SB, Thompson MA, Abrams DI, Brizz BJ, Ioannidis JP, Merigan TC. 2000. A randomized study of antiretroviral management based on plasma genotypic antiretroviral resistance testing in patients failing therapy. (CPCRA 046). AIDS 14:F83-F93.
2. Boom R, Sol CJ, Salimans MM, Jansen CL, Wertheim-van Dillen PM, van der Noordaa J. 1990. Rapid and simple method for purification of nucleic acids. J Clin Microbiol 28:495-503.
3. Chaix-Couturier C, Holtzer C, Phillips KA, Durand-Zaleski I, Stansell J. 2000. HIV-1 drug resistance genotyping. A review of clinical and economic issues. Pharmacoeconomics 18:425-433.
4. Clevenbergh P, Durant J, Halfon P, del Giudice P, Mondain V, Montagne N, Schapiro JM, Boucher CA, Dellamonica P. 2000. Persisting long-term benefit of antiviral genotypic guided treatment for HIV-infected patients failing HAART. The Viradapt Study: Week 48 follow-up. Antivir Ther 5:65-70.
5. Cohen CJ, Hunt S, Sension M, Farthing C, Conant M, Jacobson S, Nadler J, Verbiest W, Hertogs K, Ames M, Rinehart AR, Graham NM, VIRA3001 Study Team. 2002. A randomized trial assessing the impact of phenotypic resistance testing on antiretroviral therapy. AIDS 16:579-588.
6. D'Aquila RT, Schapiro JM, Brun-Vezinet F, Clotet B, Conway B, Demeter LM, Grant RM, Johnson VA, Kuritzkes DR, Loveday C, Shafer RW, Richman DD, International AIDS Society, USA. 2002. Drug resistance mutations in HIV-1. Top HIV Med 10: 21-25.
7. De Luca A, Cingolani A, Di Giambenedetto S, Trotta MP, Baldini F, Rizzo MG, Bertoli A, Liuzzi G, Narciso P, Murri R, Ammassari A, Perno CF, Antinori A. 2003. Variable prediction of antiretroviral treatment outcome by different systems for interpreting genotypic human immunodeficiency virus type 1 drug resistance. J Infect Dis 187:1934-1943.
8. Descamps D, Calvez V, Collin G, Cécille A, Apetrei C, Damond F, Katlama C, Matheron S, Huraux JM, Brun-Vezinet F. 1998. Line probe assay for detection of human immunodeficiency virus type 1 mutations conferring resistance to nucleoside inhibitors of reverse transcriptase: Comparison with sequence analysis. J Clin Microbiol 36:2143-2145.
9. Durant J, Clevenbergh P, Halfon P, Delgiudice P, Porsin S, Simonet P, Montagne N, Boucher CA, Schapiro JM, Dellamonica P. 1999. Drug-resistance genotyping in HIV-1 therapy: The VIRADAPT randomised controlled trial. Lancet 343:2195-2200.
10. Dybul M, Fauci AS, Bartlett JG, Kaplan JE, Pau AK. 2002. Guidelines for using antiretroviral agents among HIV-infected adults and adolescents. Ann Intern Med 137:381-433.
11. Garcia de Olalla P, Knobel H, Carmona A, Guelar A, Lopez-Colomes JL, Cayla JA. 2002. Impact of adherence and highly active antiretroviral therapy on survival in HIV-infected patients. J Acquir Immune Defic Syndr 30:105-110.
12. Garcia F, Palomares JC, Martinez NM, Álvarez M, Suarez S, Perea EJ, Rodriguez JM, Hernández-Quero J, Maroto MC. 2003. Study of different systems for interpreting results of genotypic antiretroviral drug resistance test. Antivir Ther 8:198-199.
13. Halfon P, Durant J, Clevenbergh P, Carsenti H, Celis L, Khiri H, De Smet K, Girard P, De Brauwer A, Hulstaert F, Dellamonica P. 2001. Line probe assay (INNO-LiPA) is more sensitive than sequencing for detection of minor HIV-1 variants within structured treatment interruption. 8th European Conference on Clinical Aspects and Treatment of HIV-infection (ECCATH), 28-31 October, 2001, Athens, Greece.
14. Hanna GJ, D'Aquila RT. 2001. Clinical use of genotypic and phenotypic drug resistance testing to monitor antiretroviral chemotherapy. Clin Infect Dis 32:774-782.
15. Meynard JL, Vray M, Morand-Joubert L, Race E, Descamps D, Peytavin G, Matheron S, Lamotte C, Guiramand S, Costagliola D, Brun-Vezinet F, Clavel F, Girard PM, Narval Trial Group. 2002. Phenotypic or genotypic resistance testing for choosing antiretroviral therapy after treatment failure: A randomized trial. AIDS 16: 727-736.
16. Perno CF, Ceccherini-Silberstein F, De Luca A, Cozzi-Lepri A, Gori C, Cingolani A, Bellocchi MC, Trotta MP, Piano P, Forbici F, Scasso A, Vullo V, d'Arminio Monforte A, Antinori A, AdICoNA Study Group. 2002. Virologic correlates of adherence to antiretroviral medications and therapeutic failure. J Acquir Immune Defic Syndr 31: S118-S122.
17. Schmit JC, Ruiz L, Stuyver L, Van Laethem K, Vanderlinden I, Puig T, Rossau R, Desmyter J, De Clercq E, Clotet B, Vandamme AM. 1998. Comparison of the LiPA HIV-1 RT test, selective PCR and direct solid phase sequencing for the detection of HIV-1 drug resistance mutations. J Virol Methods 73:77-82.
18. Setti M, Bruzzone B, Ansaldi F, Borrelli P, Indiveri F, Icardi G. 2001. Identification of key mutations in HIV reverse transcriptase gene can influence the clinical outcome of HAART. J Med Virol 64:199-206.
19. Sturmer M, Doerr HW, Staszewski S, Preiser W. 2003. Comparison of nine resistance interpretation systems for HIV-1 genotyping. Antivir Ther 8:239-244.
20. Stuyver L, Wyseur A, Rombout A, Louwagie J, Scarez T, Verhofstede C, Rimland D, Schinazi RF, Rossau R. 1997. Line probe assay for rapid detection of drug-selected mutations in the human immunodeficiency virus type 1 reverse-transcriptase gene. Antimicrob Agents Chemother 41:283-291.
21. Suarez A, Picazo J, Alonso R, Bouza E, Delgado R, Rodriguez-Noriega A, Bernal A, Garcia A. 2002. Comparison of three genotyping methods for the detection of HIV-1 resistance to antiretroviral drugs. Rev Esp Quimioter 15:43-54.
22. Tural C, Ruiz L, Holtzer C, Schapiro J, Viciana P, González J, Domingo P, Boucher C, Rey-Joly C, Clotet B. 2002. Clinical utility of HIV-1 genotyping and expert advice: The Havanna trial. AIDS 16:209-218.
23. Van Laethem K, Van Vaerengerg K, Schmit JC, Sprecher S, Hermans P, De Vroey V, Schuurman R, Harrer T, Witvrouw M, Van Wijngaerden E, Stuyver L, Van Ranst M, Desmyter J, De Clercq E, Vandamme AM. 1999. Phenotypic assays and sequencing are less sensitive than point mutation assays for detection of resistance in mixed HIV-1 genotypic populations. J AIDS 22:107-118.
24. Van Vaerenbergh K, Van Laethem K, Van Wijngaerden E, Schmit JC, Schneider F, Ruiz L, Clotet B, Verhofstede C, Van Wanzeele F, Muyldermans G, Simons P, Stuyver L, Hermans P, Evans C, De Clercq E, Desmyter J, Vandamme AM. 2000. Baseline HIV type 1 genotypic resistance to a newly added nucleoside analog is predictive of virologic failure of the new therapy. AIDS Res Hum Retrovirus 16:529-537.